Press Releases & News

Press Release | 24 Oct, 2024

Glenmark Life Sciences reports revenue of Rs. 5,069 Mn for Q2FY25, Gross margins of 55.6%, up 450 bps QoQ

Press Release | 25 July, 2024

Glenmark Life Sciences reports revenue growth of 9.7% QoQ for Q1FY25, EBITDA margins of 28%, up 110 bps QoQ

Press Release | 25 April, 2024

Glenmark Life Sciences reports revenue growth of 5.6%, EBITDA margins of 30.1% in FY24

Press Release | 12 March, 2024

Nirma Limited acquires majority stake in Glenmark Life Sciences

Press Release | 23 Jan, 2024

Glenmark Life Sciences reports quality revenue growth of 5.9% YoY Delivers robust EBITDA growth of 14.6% YoY; EBITDA margins at 30.4%

Press Release | 19 Jan, 2024

Glenmark Life Sciences announces another CDMO deal

Press Release | 20 Oct, 2023

Glenmark Life Sciences Strong Growth Momentum Continues, Revenue Surges 17% YoY to Rs. 5,954 Mn in Q2FY24

Press Release | 21 July, 2023

Glenmark Life Sciences maintains strong growth momentum, reports robust 25% EBITDA growth in Q1FY24

Press Release | 27 April, 2023

Glenmark Life Sciences sustains strong growth momentum in Q4FY23

Press Release | 27 January, 2023

Revenue growth of 6% QoQ Strong growth in India, Europe and LATAM with recovery in US business

Press Release | 21 Oct, 2022

Revenue growth of 4% QoQ Regulated markets led the growth

Press Release | 04 Aug, 2022

PAT growth of 7.7% YoY for Q1 FY23 CVS and CNS therapies lead the growth of the generic API portfolio

Press Release | 20 April, 2022

Glenmark Life Sciences reports revenue growth of 10% YoY for Q4 FY22; 12.6% for the full year, FY22

Press Release | 8 February, 2022

Glenmark Life Sciences reports revenue growth of 4.5% and PAT growth of 11.1% YoY for Q3 FY22

Press Release | 10 November, 2021

Glenmark Life Sciences reports revenue growth of 7.9% and PAT growth of 59.0% YoY for Q2 FY22 Declares interim dividend of ₹10.5 per share

Press Release | 13 August, 2021

Glenmark Life Sciences reports revenue growth of 32.2% and PAT growth of 24.5% YoY for Q1 FY22

Press Trust of India | 07 May, 2019

Glenmark Appoints Dr. Yasir Rawjee as Chief Executive Officer of Glenmark Life Sciences, its Subsidiary for the API Business